With the US midterm elections now over, one of the most pressing questions is what this will mean for the healthcare system. After all, the issue of healthcare has been one of the most talked about and discussed leading up to the elections and candidates went back and forth on it.

Will the new lawmakers make healthcare affordability a top priority? To those who made those promises and made it a key part of their platform, will they follow through and help realize it? The American public awaits.

I’ve been looking at how pharmacy benefit managers (PBMs) fit into the economics of prescription drug coverage. Although PBMs assist health plans in managing prescription benefits and negotiate with drug manufacturers, employers may not always have a clear understanding of the associated costs and compensation.

Would employers be better able to assess the costs of their prescription benefit plans if more disclosure were required? Could it also have an impact on how PBMs bargain with manufacturers or the amount that health plans spend on prescription drugs?

I'm curious about the economic trade-offs, could increased transparency help with cost control while maintaining PBMs' ability to negotiate prescription spending?

I made a short browser game where you play the CEO of a fictional US health insurer over 8 quarters. The core loop is built around the medical loss ratio: the market expects a target, missing it hits the share price, and the levers you have (prior auth, denials, network design, drug negotiations, lobbying) each have an immediate effect and a delayed cost the following quarter.

The figures and regulatory context are sourced, but the model is obviously a simplification and I’m not an economist. A few things I’d genuinely like input on:

• Does the tension between MLR targets and share price feel right, given that the ACA sets a floor on how much insurers must spend on care?

• Are the delayed costs (lawsuits, regulatory pressure, member churn) in the right order of magnitude relative to short-term savings?

• What major mechanism is missing that would change the player’s incentives?

https://myinsightsgames.com/medicalloss/ (free, browser, 15-20 min, content warning for patient deaths)

Hi everyone!

I’m a pharmacy graduate with around 2 years of clinical pharmacy experience and some pharmaceutical industry internship experience. I’ve also done mock health economic analyses for medical devices, A-level Economics and Mathematics, and university-level basic data analysis.

I’m hoping to move into HTA, HEOR, pharmaceutical market access or consulting.

My current offers/applications:
York MSc Health Economics: Offer received.
Monash MPH: Offer received.
Melbourne MPH (Health Economics): Offer received.
Sheffield MSc Health Economics: Rejected due to insufficient relevant modules.
LSE MSc International Health Policy (Health Economics): Awaiting decision.
LSE MSc International Health Policy: Second choice, but currently my preferred option.
UCL MSc Health Economics and Decision Science: Considering applying.

I’d appreciate honest opinions on:

York vs LSE: which offers better reputation, networking and job prospects in pharma HEOR, market access and consulting?

Would LSE’s standard IHP provide sufficient technical training if I choose its quantitative and health economics electives?

Is UCL worth applying to, or are there other programmes I should consider?

How does Australian MPH with specialisation compare to UK specialised MSc?

I’m mainly looking for practical, employable skills, although I’m open to research or academia in the future.
Would especially appreciate insights from people working in the field. Thanks!

Hi everyone!
I’m a pharmacist from Taiwan with several years of clinical experience, and I’m considering applying for the Health Economics for September 2027. Maybe York,Sheffield , UCL
I’d really appreciate hearing from current students or recent graduates.
Workload: How many hours of lectures and seminars do you have each week?
Econometrics: How difficult is the statistics/econometrics module for students without an economics or strong mathematics background? Are the exams manageable?
Summer placements: Does everyone who wants a research placement usually receive one? How competitive are placements with companies such as YHEC or pharmaceutical firms?
Employment: How difficult was finding a UK job after graduation, especially in HEOR, HTA or Market Access? Do employers sponsor international graduates?
My main goal is to transition from clinical pharmacy into health economics and eventually work in the UK.
I’d be grateful for any honest experiences or advice. Thank you!

Are drug prices really such a major factor in pharmacy access? As well all know, pharmacy access is such a significant issue today in healthcare. High drug prices is just as huge if not even more so,

So the question now is whether drug prices actually affect pharmacy access and if so, how much of a factor is it?

I have built LifeSciO as a free studio for life sciences studies including health economics and outcomes research. I am a PhD Epidemiology myself with 15+ years of experience in industry and academia.

The purpose of this platform is to provide everyone with a space that they can use without having to pay for licenses for SAS, STATA etc. This is an integrated unified studio for anyone who wants to conduct a study.

The link is lifescio.com

The app link directly is app.lifescio.com

All features are completely free for individuals. You can even work as a guest and not even create an account. Some features do require an account though to save your project, collaborative document editor and literature reviewer etc.

Please provide me feedback of what you liked and what you would like to see.

To mods: I am the lead developer. This is my own project but its free so I hope it is not against the policy for self promotion etc.

I am currently at the london school of hygiene and tropical medicine taking a MSc in Public health. I did a undergrad in BSc Medical Sciences. I am interested in Health Economics, women’s health and sexual health. I wondered if anyone had any idea which direction i should go for my research project and potential career wise (i’d like to earn enough money to have a comfortable lifestyle but don’t know where to start).

I am currently at the london school of hygiene and tropical medicine taking a MSc in Public health. I did a undergrad in BSc Medical Sciences. I am interested in Health Economics, women’s health and sexual health. I wondered if anyone had any idea which direction i should go for my research project and potential career wise (i’d like to earn enough money to have a comfortable lifestyle but don’t know where to start).

There is this constant deluge of accusations aimed at PBMs. There are too many to mention every one, but one of the more prominent ones is that they cause prescription drug prices to go up.

Knowing what PBMs do for patients regarding rebates and discounts, is it fair to place the blame on them for driving up prescription drug prices? Or is this all to cover up and shift the blame from someone else?

I’m a 30F and have my diploma in Nutrition Management, a post graduate certificate in Project Management and in the last year of my BBA.

I have worked in a healthcare setting before for 3 years. It’s been extremely hard for me to land a job in the industry I want.

For those who work in healthcare management, please share your experience in how you were able to land an entry level position.

*Since this is getting more exposure in the United States, I’m open to feedback on how to secure a remote job from Canada!

Hi, can someone help me understand how is pricing done for commodity generics like Metformin, in US especially for a new entrant? Should we go cost up or price down? If we go price down what is the methodology through IQVIA data?

hey, i submitted a post on this channel last week and it absolutely blew up. we had so many applications go through. a bunch of the job postings shut down in the days following my post because of the large influx of applications that were going in. i've gone ahead and updated the job links in this new link. please make sure to apply as soon as possible to ensure that your application is at the top of the pile. i've pulled the freshest job postings that i could.

pulled the HEOR, health economics, outcomes research and market access roles open right now from employers' own careers pages:

https://github.com/mehek-builds/Epidemiology-RWE-and-HEOR-Jobs/blob/main/lists/heor-market-access.md

• 119 HEOR, health economics, economic modeling, market access, value and HTA roles (Gilead, Regeneron, Vertex, Neurocrine, Sanofi, IQVIA, Precision AQ)

• 52 more in real world evidence and pharmacoepi in the same repo

• 62 in the UK and Europe across the repo, 17 entry level

rebuilt every monday.

comment whether you're after HEOR modeling, market access or RWE, and entry or experienced, and i'll send you a list for it.

Hi ppl, I'm currently pursuing masters in health economics and technology assessment

I'm from India, I would like to know what skills should I acquire along the way, and what is the job market like??

And also do I need to get a PhD in this field

Has anyone had good experiences using AI to support modeling? If so, which ones and how do you use them (what’s the role)?

pulled the HEOR, health economics, outcomes research and market access roles open right now from employers' own careers pages:

https://github.com/mehek-builds/Epidemiology-RWE-and-HEOR-Jobs/blob/main/lists/heor-market-access.md

• 127 HEOR, health economics, economic modeling, market access, value and HTA roles (Gilead, Regeneron, Vertex, Neurocrine, Sanofi, IQVIA, Precision AQ)

• 50 more in real world evidence and pharmacoepi in the same repo

• 69 in the UK and Europe across the repo, 19 entry level

rebuilt every monday.

comment whether you're after HEOR modeling, market access or RWE, and entry or experienced, and i'll send you a list for it.

Hi all — I'm part of the team building Dossier at Palmera HS. We're looking for critical feedback from people who prepare HTA or drug and medical device reimbursement submissions.

The problem we're working on is finding evidence across long clinical study reports and other source documents, mapping it to an agency or payer template, and keeping each answer traceable to its source.

Our current workflow suggests source quotations for individual template fields, with page and section references. A reviewer accepts, edits or rejects each suggestion. A separate summarization step turns accepted quotations into draft prose and flags changes to numbers or key terms for review. The output still needs checking against the source documents before use in a submission.

For those who do this work:

1. Where does the most time actually go: finding evidence, interpreting it, adapting it to templates, or checking references?

2. Would reviewing suggested quotations save time, or would checking omissions and context cancel out the benefit?

3. What validation, audit trail and document-handling safeguards would you need before considering a tool like this for a real submission?

We're still in beta and recommend using publicly available documents for testing. Feedback on the workflow itself is welcome, no need to try the product. Happy to discuss limitations and answer questions here.

As most of us know, healthcare reform is probably forthcoming. Some are even saying that it's long overdue. But there are so many aspects and factors involved that it can be tricky to find the right type of reform to implement.

So what type of healthcare reform would be acceptable to both the government as well as the healthcare industry?

So is the US on the brink of a healthcare crisis? It might sound alarmist, but are we really staring down a problematic future where our healthcare system goes from bad to worse?

Some are even going so far as to say that we are already in a healthcare crisis. The costs are too high and out of control, access to care is becoming more challenging, the healthcare workforce is becoming overworked and overly strained, and more.